Adaptor proteins Grb7 and Grb2 have been implicated as being 2 potential therapeutic targets in several human cancers, especially those that overexpress ErbB2. These 2 proteins contain both a SH2 domain (Src homology 2) that binds to phosphorylated tyrosine residues contained within ErbB2 and other specific protein targets. Two assays based on enzyme-linked immunosorbent assay and fluorescence polarization methods have been developed and validated to find and rank inhibitors for both proteins binding to the pY 1139 . Fluorescence polarization assays allowed the authors to determine quickly and reproducibly affinities of peptides from low nanomolar to high micromolar range and to compare them directly for Grb7 and Grb2. As a result, the assays have identified a known peptidomimetic Grb2 SH2 inhibitor (mAZ-pTyr-(αMe)pTyr-Asn-NH 2 ) that exhibits the most potent affinity for the Grb7 SH2 domain described to date. (Journal of Biomolecular Screening 2008:112-119) 
INTRODUCTION
G RB7 IS A MEMBER OF AN EMERGING FAMILY of adaptor signaling proteins that is devoid of intrinsic enzymatic activity, similar to Grb2, Shc, and Nck. This multidomain protein is recruited via its SH2 (Src homology 2) domain to a variety of activated tyrosine kinases (PTKs), including ErbB receptors, [1] [2] [3] [4] focal adhesion kinase (FAK), 5 PDGF-R, 6 c-Kit/SCF-R, 7 Ret, 8 and Tek/Tie. 9 The Grb7 SH2 domain also binds to the protein tyrosine phosphatase SHPTP2 10 and to the adaptor protein Shc, 2 but the functional consequences of the association of Grb7 with its physiological ligands have not been completely elucidated.
The importance of Grb7 in tumor progression has been firmly established by numerous studies. First, Grb7 is amplified and overexpressed in concert with ErbB2 in breast, esophageal, and gastric cancers. 11 Second, an interaction between Grb7, ErbB2, and NF-κβ-inducing kinase (NIK) provided a relationship between ErbB/Grb7 overexpression and downstream inflammation and promoted a favorable environment for the initiation and progression of cancer. 12 Furthermore, a potential role for Grb7 in enhanced focal adhesion kinase (FAK)-mediated cell migration was studied in particular by several laboratories 13 and raised speculation that cancers that overexpress Grb7 may be prone to metastasis. Therefore, molecular interactions involving Grb7 and its limited tissue distribution 14 provide Grb7 as a potential target for therapeutic intervention.
Phosphopeptide competition and site-directed mutagenesis revealed that the SH2 domain of Grb7 strongly binds to Tyr-1139 of ErbB2. 3 This also corresponds to the major Grb2 binding site. To our knowledge, only 1 nonphosphorylated cyclic peptide was described to inhibit Grb7 SH2/ErbB binding (IC 50 25 μM) without inhibiting Grb2 SH2/ErbB interaction. 15 This peptide inhibitor was tested on MiaPaca2 cells and was found to selectively block both interaction between Grb7 and FAK and phosphorylation of Grb7. Moreover, said peptide significantly attenuated cell migration and peritoneal metastasis of the pancreatic Grb7-expressing cancer cells in a mouse model. 16 Two methods have been described to probe the binding of ligands to the Grb7 SH2 domain. These include surface plasmon resonance (BIAcore) 3 and isothermal titration calorimetry (ITC). 17 Unfortunately, these assays are not suitable for highthroughput screening (HTS). Recently, equilibrium dissociation constants of each domain for 61 peptides representing physiological sites of tyrosine phosphorylation on the 4 ErbB receptors were measured for SH2 protein, including Grb7, using the protein microarrays technique. 18 To find new blockers of Grb7 SH2 interactions, we found it useful to develop fast screening tests. Fluorescence polarization (FP) or fluorescence anisotropy (<r>) assays are suitable for the analysis of binding between a small fluorescence-labeled molecule and its significantly larger binding partner. 19 The 2 underlying principles of fluorescence polarization assays are as follows: (1) polarized light excites the fluorophore attached to the small binding partner, and (2) the rotational speed of a molecule in solution inversely correlates with its effective molecular weight. FP measures changes in the orientation of plane polarized light brought about by fluorophores that undergo significant molecular motion during their fluorescence lifetime.
Previous studies have successfully used these assays for a number of targets, including the Src-SH2 domain. 20 There are several advantages for using fluorescence polarization in HTS. First, the assay is performed in a homogeneous solution, which eliminates possible complications that arise from solid-phasebased assays. The signal is not influenced by a change in intensity brought by tracer concentration changes. Thus, the free and bound probe exhibits 2 different fluorescence polarization values; this difference can be exploited to directly quantify the bound state without the necessity to separate the 2 species. The equilibration time is short and reduces overall assay time. Second, fluorescence polarization is measured in ratio mode, which avoids intensity fluctuation and, to a certain degree, the inner filter effect created by absorbing coloured compounds. Third, there is no radioactivity involved and no waste disposal cost. Last, the method can be applied to inhibitors exhibiting a weak or strong binding constant.
Herein, we describe the development and validation of fluorescence polarization assays for measuring the binding of compounds to the SH2 domains of Grb7 and Grb2. In these assays, we use the same labeled peptide that presents different affinities for the aforementioned 2 proteins. These homogeneous assays are suitable for screening small molecules in DMSO. They are simple, are extremely sensitive, and provide a viable option for easy automation and could distinguish between nM and μM inhibitors.
MATERIALS AND METHODS

Expression and purification of GST-Grb7 SH2 domain
GST-Grb7 SH2 (residues 431-512) was produced in bacteria Escherichia coli BL21 according to the manufacturer's protocol (GE Healthcare, Chalfont St. Giles, UK). Bacteria were induced by 0.1 mM isopropyl β-D-thiogalactopyranoside (IPTG) at 37 °C for 2 h, 30 min. The bacteria pellet was then suspended in lysis buffer (50 mM HEPES (4-(2-hydroxyethyl)-1-piperazine ethanesulfonic acid, pH 7.5), 150 mM NaCl, 10% glycerol, 1% Triton X-100, 1.5 mM MgCl 2 , 1 mM EGTA, 10 μg/mL aprotinin, 10 μg/mL leupeptin, 100 mM NaF, 10 mM sodium pyrophosphate, and 1 mM phenylmethylsulfonyl fluoride containing 1 mg/mL of lysozyme (1 mL of buffer for 50 OD units of the cell culture).
Bacteria were lysed by sonication, and after centrifugation, clarified supernatants were incubated overnight at 4°C with glutathione-Sepharose beads (GE Healthcare; 30 μL of 50% beads per mL of supernatant). Beads were then washed 3 times with HNTG buffer (20 mM HEPES [pH 7.5], 150 mM NaCl, 10% glycerol, 0.1% Triton X-100, 1 mM phenylmethylsulfonyl fluoride). The resulting fusion protein was eluted with 10 mM reduced glutathione in 50 mM Tris-HCl (pH 8) and quantified by 10% sodium dodecyl sulphate-polyacrylamide gel electrophoresis (SDS-PAGE) analysis. The purity estimated on the gel was over 90%.
Grb2 production, purification, and dialysis
Grb2 was expressed in E. coli BL21 (DE3) cells transformed with the plasmid pET11d-Grb2 (gift from A. Ducruix), purified, and dialyzed as previously described. 21 Purity of Grb2 was checked by the high-performance liquid chromatography (HPLC) method using a C4 (250-mm) Vydac column. A linear gradient (from 10% to 90% of B in buffer A, where A = 0.1% trifluoroacetic acid in water and B = 70% acetonitrile and 0.09% trifluoroacetic acid) for 30 min at a flow rate of 1 mL/min with detection at 214 nm was used. Grb2 was eluted at 22.9 min, and its purity was 98% in these conditions.
Synthesis of peptide inhibitors and fluorescent peptides
All peptides were synthesized by Merrifield stepwise solidphase synthesis on an Applied Biosystems A433 automated peptide synthesizer (Applied Biosystems, Foster City, CA) using FastFmoc chemistry. All amino acids from Applied Biosystems were N-terminal protected by Fmoc, and their side chains were protected by classical protecting groups. Fmoc-Tyr(PO 3 -MDPSE 2 )-OH (MDPSE: methyldiphenylsilylethyl) was purchased from Bachem, Inc. (Torrance, CA).
For the peptidic inhibitors synthesis, the first amino acid was loaded onto a Rink amide resin (Applied Biosystems) by O-(Benzotriazol-1-yl)-N,N,N',N'-tetramethyluronium hexafluorophosphate (HBTU). HBTU (0.45 M) in N,N-dimethylformamide (DMF) was used as coupling reagent. Fmoc deprotection at each step was carried out using 20% of piperidine in N-methylpyrrolidone (NMP). Peptides were cleaved from resin with simultaneous removal of side chain protecting groups by treatment with 95% trifluoroacetic acid that contained 2.5% water and 2.5% triisopropylsilane for 4 h at room temperature.
For the fluorescent-labeled peptides with 2 different fluorescent markers, peptidyl resin (Ahx-pYVNQ, 0.1 mmol) was performed as above. The fluorescein derivative 22 (418.2 mg, 1 mmol) was then coupled directly on the resin to the peptidic probe (see Fig. 1 ) in NMP overnight, using (benzotriazol-1-yloxy)tris-(dimethylamino) phosphonium (BOP) (442.3 mg, 1 mmol), N-hydroxybenzotriazole (HOBt) (153.1 mg, 1 mmol), and diisopropylethylamine (DIEA) (523 μL, 3 mmol). The resin was filtered, washed 4 times with NMP and 2 times with dichloromethane, and dried. The resulting fluorescent peptidyl resin was then cleaved with a mixture of TFA/TIPS/H 2 O (9.5/0.25/0.25 in volume) for 4 h at room temperature.
In both cases, the filtrate from the cleavage reaction was evaporated, precipitated in diethyl oxide, collected by centrifugation, and lyophilized. Crude peptides were purified by semipreparative HPLC on a Nucleosil C18 column (Vydac, 5 μm, 10 × 250 mm) with a gradient program (solvent A is water with 0.1% trifluoroacetic acid, and solvent B is 70% acetonitrile aqueous solution with 0.09% trifluoroacetic acid) at a flow rate of 2 mL/min with UV detection at 214 nm. Fractions were analyzed by analytic HPLC on a Nucleosil C18 column (Vydac, 5 μm, 4.6 × 250 mm), and the pure fractions were collected and lyophilized. The identity of peptides was checked by electrospray mass spectrometry.
The mAZ-pTyr-(αMe)pTyr-Asn-NH 2 peptide was synthesized and purified using the procedure described. 23
Enzyme-linked immunosorbent assay on Grb7 SH2 domain
Precoated streptavidin plates (StreptaWell High Bind, Roche Diagnostics, Basel, Switzerland) were incubated with 100 μL/well of Biotin-Ahx-PQPEpYVNQPD-NH 2 peptide (40 nM in Tris buffer saline [TBS] buffer [137 mM NaCl, 10 mM Tris, pH 7.4]) prepared from the TBS buffer 20× ready pack (Interchim, Montlucon Cedex, France) overnight at 4 °C. Nonspecific binding was blocked with TBS/3% bovine serum albumin (BSA) (GAU BSA 01-65 fraction 3, EuroBio, Les Ulis, France) overnight at 4 °C. Peptidic competitors were incubated at the appropriate concentration in TBS/3% BSA containing 20 nM GST-Grb7 SH2 protein (100 μL/well) overnight at 4 °C. Color development was made after peroxidase-coupled anti-glutathion S transferase (GST) incubation (Santa Cruz Biotechnology, Inc., Santa Cruz, CA; (sc-138 HRP) 1/500 in TBS/3% BSA/0.1% Tween-20), using the 3,3,5,5-tetramethylbenzidine (TMB) solution (Interchim). Reaction was stopped with H 2 SO 4 (10% v/v) after coloration, and the optical density was read at 450 nm.
Enzyme-linked immunosorbent assay on Grb2 SH2 domain
The enzyme-linked immunosorbent assay (ELISA) on the Grb2 SH2 domain was already described 23 and was improved using only 1 antibody for color development (peroxidase-coupled anti-GST [Santa Cruz Biotechnology, Inc.], (sc-138 HRP)). The same procedure was used, except for reagents concentration: 100 μL/well of Biotin-Ahx-PSpYVNVQN-NH 2 peptide (1.5 μM in TBS buffer, 137 mM NaCl, 10 mM Tris, pH 7.4) prepared from TBS buffer 20× ready pack (Interchim) overnight at 4 °C. Peptidic competitors were incubated at the appropriate concentration in TBS/3% BSA containing 2.6 nM GST-Grb2 protein (from Santa Cruz Biotechnology, Inc., ref sc-4015, 100 μL/well) overnight at 4 °C.
In both cases, dose-response relationships were constructed by nonlinear regression of the competition curves with GraphPad 4.03 software (GraphPad Software, Inc., San Diego, CA) using nonlinear regression.
FP measurements
FP measurements were done on a 384-well microplate reader Envision 2.0.1 (Wallac, PerkinElmer Life Sciences and Analytical Sciences, Turku, Finland). FP is defined by the following equation:
where I ʈ and I ⊥ are the fluorescence intensities (FI) in the emission beam of the ligand with polarization parallel or perpendicular to that of incident light. Polarization is closely related to anisotropy, which is an alternative system that relates these measurements. In fact, polarization is twice the fraction of light that is polarized. It is useful to express the measurements as millipolarization units (mP):
where G is a grating factor near the value of 1 and is used to adjust for slight differences in the 2 employed optical paths (according to the manufacturer's information). which X is the logarithm of concentration, and Y is the bound form. Data plotting, nonlinear regression analysis, and curve construction were performed using GraphPad 4.03 software.
Determination of the equilibrium dissociation constants (K d ) of fluorescent peptides toward the SH2 domains of Grb2 and Grb7
Binding affinities of the fluorescent F-pY 1139 (Fluo-Ahx-pYVNQ-NH 2 or SRB-Ahx-pYVNQ-NH 2 ) toward Grb2 and GST-Grb7 SH2 domains, respectively, were measured in Costar 384-well half-area black plates (Corning 3676) at room temperature (~20 °C). We assumed that evaluated affinity measurements are comparable for the SH2 domains of Grb7 and Grb2 in the context of Grb2 as a whole protein. Using a set of polarization fluorescence filters (Wallac, PerkinElmer), the excitation was set at 480 nm (bandwidth 30 nm) and emission at 535 nm (bandwidth 40 nm). To each well, 0.5 μL of fluorescent peptide (final concentration: 50 nM) was added to a final volume of 5 μL. This increased the final concentration of the GST-Grb7 SH2 domain (from 0-1300 μM) or Grb2 (from 0-6 μM), respectively, in the assay buffer (100 mM NaCl, 20 mM Na 2 HPO 4 /NaH 2 PO 4 , 2 mM dithiothreitol [pH 7.2], 1% DMSO). The plate was mixed for 5 min and incubated at room temperature for 30 min to reach equilibrium.
Fluorescence polarization assay
Competitive binding experiments were performed in Costar 384-well half-area black plates by using the fluorescein derivativelabeled F-pY 1139 as a fluorescent probe. For both fluorescence polarization assays on Grb2 and GST-Grb7 SH2, 5 μL of F-pY 1139 (final concentration 20 nM) was preincubated with 5 μL of Grb2 (final concentration: 0.83 μM) or with GST-Grb7 SH2 (final concentration: 1.13 μM for ErbB2 1139 -derived peptide competitive assay and 5.13 μM for Shc 317 -derived peptide competitive assay) in the assay buffer for 30 min at room temperature in each well. A 5-μL sample of the tested solution was added, and fluorescence polarization values were measured after a 30-min competition time. K i values were calculated using the equation described by Nikolovska-Coleska et al. 24 ,*
RESULTS AND DISCUSSION
Affinity analysis by ELISA
We first developed an ELISA assay on the SH2 domain of Grb7 using a biotinylated pY 1139 ErbB2-derived decapeptide (Biotin-Ahx-PQPEpY 1139 VNQPD-NH 2 ; Fig. 1) . ELISA assay on the Grb2 SH2 domain was adapted from a procedure previously described in our laboratory. 23 Competition results on each test by several ErbB2 pY 1139 -shortened sequences were also obtained.
As can be seen in Table 1 , the biotinylated decapeptide had an IC 50 of 5 μM and 7 μM for the Grb7 SH2 and Grb2 SH2 domain, respectively. The shortened tetrapeptide sequence exhibited a significant decrease in affinity for the Grb2 SH2 domain (286 μM); however, compared to that of the 10-mer or 6-mer peptide, it did not show a significant variation of IC 50 values for the Grb7 SH2 domain. This gap for the Grb2 SH2 domain was also observed between Ac-pYVNQ-NH2 and pYVNQ-NH2 (Table 1) , which underlies the importance of the N-1 amino acid carbonyl group interaction with the SH2 domain of Grb2. Said type of interaction was reported using a pYINQ sequence by Furet and al. 25 In addition, the results for the Grb7 SH2 domain are consistent with the observations of the nuclear magnetic resonance (NMR) structure of the Grb7 SH2/ErbB2 peptide complex (PDB: 1MW4). Analysis of the hydrogen bonds network in the complex between Grb7 SH2 and the PQPEpY 1139 VNQPD-NH 2 indicated a minimal interaction sequence corresponding to the pYVNQ tetrapeptide motif. 26 However, comparisons of these results are only pertinent within the same protein assay. Direct comparisons of IC 50 results between different target ELISA assays are inconclusive, and calculation of the corresponding K i s cannot be assessed because the concentration of the ligand cannot be accurately estimated (as required for Cheng-Prusoff treatment of the results 27 ). 
Peptidic Inhibitors GST-Grb7 SH2 GST-Grb2
Biotin-Ahx-PQPEpYVNQPD-NH 2 5.11 ± 1.12 7.00 ± 1.30 PEpYVNQ-NH 2 1.10 ± 0.20 9.30 ± 1.82 EpYVNQ-NH 2 1.53 ± 0.25 95 ± 20 pYVNQ-NH 2 3.57 ± 0.64 286 ± 57 Ac-pYVNQ-NH 2 3.40 ± 0.57 90 ± 15 mAZ-pY(αMe)pYN-NH 2 0.30 ± 0.07 0.012 ± 0.002
Inhibitory activity of some ErbB2 pY 1139 -derived peptides and a peptidomimetic sequence against Grb7 and Grb2 SH2 domains was determined using the enzymelinked immunosorbent assay (ELISA) technique. Dose-response relationships were constructed by nonlinear regression of the competition curves with GraphPad 4.03 software using nonlinear regression. IC 50 values were determined by nonlinear regression (curve fit) using a 1-site competition binding model. * The following equation was used to calculate the K i value of the given inhibitor:
The above equation shows that K i can be expressed as a function of the concentration of the free inhibitor at 50% inhibition, [I] 50 ; the concentration of the free labeled ligand at 50% inhibition, [F] 50 ; the concentration of the free protein at 0% inhibition, [SH2] 0 ; and the dissociation constant of the protein-fluorescent ligand complex, K d (http://sw16.im.med.umich.edu/software/calc_ki/). .
Saturation analyses
Direct fluorescence variations due to binding interaction were used to determine the K d on Grb2 by Cussac et al., 28 but this method did not yield results in the case of Grb7 (data not shown). Therefore, we developed another assay using fluorescence polarization. We connected the N-terminus of the sequence pYVNQ with a linker Ahx (6-aminohexanoic acid) and then labeled the peptide with a fluorescein probe. 22 This probe could be excited and analyzed under precise wavelengths (485/530 nm).
The binding affinity between Fluo-Ahx-pYVNQ-NH 2 and the Grb7 SH2 domain was obtained by evaluating the fluorescence polarization of the 50-nM fluorophore with varying concentrations of the Grb7 SH2 domain (0-1300 μM). A preliminary experiment was first performed to check that the Fluo-Ahx-pYVNQ-NH 2 probe does not bind to GST (data not shown). For the Grb7 SH2 domain, polarization progressively increased to reach saturation to result in an assay window of ΔmP = 225 ( Fig. 2A) . We determined a K d value of 17.5 ± 0.5 μM. Studies using sulforhodamine (SRB) as another probe (SRB-Ahx-pYVNQ-NH 2 ) were also performed. Fluorophore plate assay experiments with this SRB-labeled probe revealed a K d value of 18 ± 1 μM for Grb7-SH2 (data not shown), which is similar to that of the fluorescein analog. Nevertheless, this red peptide was a less sensitive fluorophore; consequently, Fluo-Ahx-pYVNQ-NH 2 was used as a probe because of its greater sensitivity.
The binding studies for the Grb2 SH2 domain were performed using the same probe (Fluo-Ahx-pYVNQ-NH 2 ). For Grb2, polarization progressively increased to reach saturation to result in an assay window of ΔmP = 102 (Fig. 2B) . We found a K d value of 220 ± 50 nM. In the case of Grb2, we did not observe any difference on peptide binding in the FP assay using either Grb2 or GST-Grb2. Moreover, we have verified that GST did not bind to phosphopeptides (data not shown). Thus, we hypothesized that the use of GST-Grb7 in FP assays had no effect on the binding of phosphopeptides on Grb7 SH2.
Saturation analysis clearly showed a much better binding affinity of the Fluo-Ahx-pYVNQ-NH 2 probe against the Grb2 SH2 domain compared with that of the Grb7 SH2 domain.
These results are in accordance with those of Jones et al., 18 who have recently described the preference of an ErbB2 pY 1139containing 17-mer peptide for Grb2 SH2 versus Grb7 SH2 using a microarray technique. A K d of 76 nM was reported for the interaction between this 17-mer peptide and Grb2 SH2 and more than 2 μM for Grb7 SH2. On the contrary, Stein et al. 2 observed by coimmunoprecipitation from SKBr-3 cells that the Grb7 SH2 domain seemed to have a better affinity for the pY 1139 ErbB2 site than the Grb2 SH2 domain. The reason for this difference is unclear; however, it is probably due to the differential phosphorylation rate of the ErbB2 receptor and a higher expression of Grb7 than that of Grb2 in SKBr-3 cells.
Fluorescence polarization effect of DMSO on the Fluo-Ahx-pYVNQ-NH 2 /Grb7 or Grb2 SH2 domain interaction
Because the compounds to be tested are often dissolved in DMSO due to weak water solubility when performing the screening of chemical libraries, we determined the effect of DMSO on the interaction between Fluo-Ahx-pYVNQ-NH 2 and the Grb7 or Grb2 SH2 domains. Concentrations of DMSO ranging from 0% to 10% were added to a mixing solution containing 5 nM Fluo-Ahx-pYVNQ-NH 2 and 82 μM Grb7 SH2. This high Grb7 SH2 concentration was chosen because of the decrease of fluorescence polarization and to allow an increase of the method's sensitivity. Indeed, the fluorescence intensity of this complex decreased by 4% at 5% DMSO and by 8% at 10% DMSO, respectively. The effect of DMSO on the fluorescence polarization was higher and showed a 32% increase of anisotropy at 5% DMSO and a 69% increase at 10% DMSO. Similar results were also observed for the fluorescent peptide alone and the interaction between Fluo-Ahx-pYVNQ-NH 2 and the Grb2 SH2 domain. These results revealed that increasing amounts of DMSO had a small effect on the fluorescence intensity of the complex obtained from Fluo-Ahx-pYVNQ-NH 2 and the Grb7 or Grb2 SH2 domain, in addition to a significant effect on the fluorescence polarization increase between free and bound states of the fluorescent probe. Therefore, it appears that the concentration of DMSO in both fluorescence polarization assays must be constant and lower than 10% to improve its sensitivity. Only 1% DMSO in buffer was subsequently used in all fluorescence polarization assays reported here.
Competitive assays against the Fluo-Ahx-pYVNQ-NH 2 complexed with the Grb7 or Grb2 SH2 domain
The ability of unlabeled peptides (pYVNQ-NH 2 and Ac-pYVNQ-NH 2 ) to reverse the fluorescence polarization increase observed for the Fluo-Ahx-pYVNQ-NH 2 binding to the Grb7 or Grb2 SH2 domain was performed to prove that the FP assay could be used to screen for inhibitors. The amount of probe chosen for the competition experiments was based on a sufficient signal-to-noise (S/N) ratio in terms of fluorescence intensity, and the protein amount was quantified using the Lowry method. For the Grb7 SH2 assay, varying concentrations of pYVNQ-NH 2 and Ac-pYVNQ-NH 2 (0.03-33 μM) were added to a mixture of 13.3 nM (final concentration) Fluo-Ahx-pYVNQ-NH 2 and 5.13 μM GST-Grb7 SH2 (final concentration). We observed for these proteins, respectively, ΔmP = 100 for Grb7-SH2 and ΔmP = 86 for Grb2. As shown in Figure 3A , a decrease in fluorescence polarization was observed. The IC 50 values for both peptides were determined to be 6.02 ± 0.87 and 6.63 ± 1.05 μM. For the Grb2 SH2 assay, varying concentrations of pYVNQ-NH 2 and Ac-pYVNQ-NH 2 (0.01-333 μM) were added to a mixture of 20 nM (final concentration) Fluo-Ahx-pYVNQ-NH 2 and 0.83 μM Grb2 SH2 (final concentration). We determined the IC 50 of 31.4 ± 6.9 and 2.01 ± 0.44 μM, respectively (Fig. 3B) .
As can be seen in Table 2 , the K i for pYVNQ-NH 2 was 5.68 and 6.33 μM against Grb7 SH2 and Grb2 SH2, respectively, whereas the K i for Ac-pYVNQ-NH 2 was 5.10 and 0.28 μM. These results correlate with K d values measured for the fluorescein derivative-labeled pY 1139 .
Then, to further show that FP assay will successfully detect inhibitors, we tested 3 other ErbB2 pY 1139 -containing peptides and Shc pY 317 -derived peptides. IC 50 and K i were determined for each compound on both Grb7 and Grb2 SH2 domains.
As shown in Table 2 , the results obtained for ErbB2 pY 1139derived 5-mer, 6-mer, and the biotinylated 10-mer peptides fit well with those observed from an ELISA-based screen ( Table 1) . Moreover, a K i value of 2.58 μM obtained by an FP assay for Biotin-Ahx-PQPEpYVNQPD-NH 2 binding to Grb7 SH2 can be compared with that of ErbB2 pY 1139 -containing sequences (PQPEpYVNQPD-NH 2 ) by isothermal titration calorimetry. 17 Using this assay, the latter peptide was determined to have a K d value of 2.2 μM.
We used Shc pY 317 -derived peptides to validate the FP assay for Grb2 and to confirm the poor affinities of said peptides for Grb7. The results obtained by FP assay for these peptides on binding to the Grb2 SH2 or Grb7 SH2 domain are reported in Table 3 . For comparison, the K d for these peptides measured by fluorescence analysis developed by Cussac et al. 28 is included in Table 3 . As shown therein, Shc pY 317 -derived peptides exhibit K i values from 22 to 105 μM for the Grb7 SH2 domain and from 12 to 667 nM for the Grb2 SH2 domain, which confirms that Shc is a better binding site for Grb2 SH2 compared with the Grb7 SH2 domain. Furthermore, K i values of these peptides for the Grb2 SH2 domain obtained by the FP assay were in accordance with K d values obtained by the fluorescence assay.
Finally, a reported peptidomimetic inhibitor (mAZ-pTyr-(αMe)pTyr-Asn-NH2), which owned a K d value of 3 nM for the Grb2 SH2 domain and inhibited Ras activation pathway on cells, 29 was evaluated using the fluorescence polarization competition assay. This molecule was confirmed to be a nanomolar inhibitor of Grb2 SH2 and was found to be a potent inhibitor of the Grb7 SH2 domain with a K i value of 264 ± 28 nM. To our knowledge, this compound is the first short peptide described to have a submicromolar binding affinity for the SH2 domain of Grb7. In our Grb7 SH2 ELISA assay, said compound was also found to easily displace the biotinylated ErbB2 pY 1139containing decapeptide with an IC 50 of 297 ± 65 nM ( Table 1) .
Statistical description of FP assay performance
Upon demonstrating that the FP assay could be able to identify hits with a high degree of confidence, the assay was also evaluated using the Z′ factor, which is a statistical parameter that assesses the performance of HTS assays. The 2 assays resulted in S/N and signal-to-background (S/B) ratios of, respectively, 15 and 4.91 for Grb2 and 12 and 2.51 for Grb7 SH2. The Z′ factor is a unitless measurement of the separation between the distribution of control data and the distribution of data representing "hits." 30 Due to a better sensitivity of the Grb2 SH2 assay and the stability of the recorded FP values compared with the Grb7 SH2 FP assay, calculation of the Z′ parameter indicates a higher confidence for the Grb2 assay (Z′ value of 0.70). The Grb7 SH2 assay could be considered a less robust assay with a Z′ value of 0.34 for HTS use. Nevertheless, comparisons with other binding techniques show that this assay is validated and can be used to determine quickly structureactivity relationships. Moreover, this value represents an acceptable level of performance for the screening of chemical compounds, which are comparable to Z′ values of 0.2 to 0.6 for assays generally described. 30 Thus, despite the fact that Z′ = 0.34, which is inferior to the value 0.5, this FP test represents an acceptable level of performance for the screening of chemical compounds.
CONCLUSION
This work has focused on the development of screening assays to identify inhibitors of Grb2 and Grb7 proteins. These 2 proteins are key adaptor proteins in different deregulated pathways involved in numerous human cancers. Grb2 and Grb7 proteins transduce mitogenic signals downstream oncoproteins such as Her2 (ErbB2), which is overexpressed in 20% to 30% of breast cancer; BcrAbl, which is expressed in chronic myeloid leukemia; or downstream growth factor receptors (epidermal growth factor receptor, platelet-derived growth factor receptor), which are also involved in oncogenic signals. Thus, Grb2 and Grb7 appear to be interesting potential therapeutic targets. Our laboratory already validated Grb2 as a therapeutic target for Her2 overexpressing cancer cells by using inhibitors of SH3 domains. 31 The assay developed in the present study will enable us to find new, efficient inhibitors for these 2 proteins.
In summary, a fluorescence polarization assay was developed to identify and rank inhibitors of the Grb7 SH2 and Grb2 SH2 domain. Development of this assay revealed that DMSO affects the interaction between Fluo-Ahx-pYVNQ-NH 2 and the Grb7 or Grb2 SH2 domain. The fluorescence polarization assay described herein is performed with microvolumes of solution and is simple, direct, fast, sensitive, and reproductive; therefore, it may represent a useful method to characterize new inhibitor candidates in an HTS approach.
The application of this method enabled us to find an inhibitor with submicromolar binding affinity for the SH2 domain of Grb7. The molecule also showed an inhibition for the Grb2 SH2 domain in vitro and on ER22 and NIH-3T3/HER2 cells. Therefore, it provides the basis of developing dual inhibitors of Grb2 and Grb7 with a potent therapeutic application in cancer treatment.
